Shots:

• The company initiates a P-II trial in 2 stages to evaluate 3 formulations, immunogenicity &  safety of SCB-2019 as a heterologous booster dose in 520 patients with COVID-19 prior vaccinated with CoronaVac or recombinant COVID-19 vaccine at multiple sites in Brazil. The trial is sponsored by IDOR & funded by Bill & Melinda Gates Foundation
• The objective is to determine the optimal vaccine formulation over the homologous booster of a recombinant COVID-19 vaccine. The results are expected in H1’22
• The SPECTRA trial data was reported in Sep 2021 showed that SCB-2019 showed a strong boosting effect on neutralizing Ab titers, favorable safety profile to support COVID-19 vaccine  as a booster vaccine

 Ref: Globenewswire | Image: Clover